Study S001395

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT06771115
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 175
Start: 2025-01-07
Primary completion: 2025-09-10
Lead sponsor: Zomagen Biosciences Ltd.
Conditions: Obesity
Interventions: DRUG:Placebo; DRUG:VTX3232 30 mg; DRUG:Placebo in combination with semaglutide; DRUG:VTX3232 30 mg in combination with semaglutide
Results posted: TRUE
Individual participant data sharing: UNDECIDED
Secondary identifiers: OTHER:J7V-MC-EOBA

Registered primary outcomes

Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) [From the first dose of study treatment to Week 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.